Givaudan first-quarter sales fell slightly amid high input costs
By Pierre Bertrand
Givaudan SA said Thursday that first-quarter sales declined slightly amid high input costs, but that it started the year with good momentum.
The Swiss flavor-and-fragrance company said its sales in the first three months of the year were 1.77 billion Swiss francs ($1.98 billion), compared with CHF1.78 billion a year earlier.
The company said sales rose by 3.6% on a like-for-like basis but declined by 0.4% on a reported basis.
On a like-for-like basis, Givaudan made CHF1.84 billion in first-quarter sales.
The result was driven by its fine-fragrance unit and what the company called sustained high levels of new business. Growth was achieved at all customer groups, particularly in high-growth markets, the company said.
Analysts had expected the company to report CHF1.8 billion in first-quarter sales and like-for-like growth of 2.6%, according to a company-provided consensus.
Givaudan said it is continuing to implement price increases to compensate for increased input costs. It said the challenging external environment continues to affect parts of its business.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
-Pierre Bertrand
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-13-23 0235ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth